Yang X, and Wang J. 2018. Precision therapy for acute myeloid leukemia. J Hematol Oncol 11:3. 10.1186/s13045-017-0543-7Yang X, Wang J. Precision therapy for acute myeloid leukemia. J Hematol Oncol. 2018;11(1):3.Precision therapy for acute myeloid leukemia. Yang X,Wang J. J Hematol...
阅读笔记0005: Precision oncology for acute myeloid leukemia using a knowledge bank approach 桃花源中的法法 心静,处处是桃花源2 人赞同了该文章 使用知识库的方法针对急性骨髓性白血病的精确肿瘤治疗 Nature Genetics 49 (3), 332-340. 2017 Jan 16。本文通讯作者是Sanger Institute & University of Cambridge...
Acute myeloid leukemia (AML) is the most common diagnosed leukemia. In older adults, AML confers an adverse outcome. AML originates from a dominant mutation, then acquires collaborative transformative mutations leading to myeloid transformation and clinical/biological heterogeneity. Currently, AML ...
Researchers at Karolinska Institutet, among others, have studied the benefit of adding an established drug as a novel targeted therapy in the treatment of acute myeloid leukemia (AML). The results suggest that the drug hydroxyurea can increase treatment efficacy at a relatively low cost. The resear...
Acute myeloid leukemia HR-MDS: High-risk myelodysplastic syndromes LAG3: Lymphocyte-activation gene 3 BsAbs: Bispecific Antibodies BiTE: Bispecific T-cell engager NMPA: The National medical products administration FDA: Food and drug administration ...
Acute myeloid leukemia (AML) is a cancer of the bone marrow and the blood. If left untreated, it develops rapidly and can cause death within weeks or months. While there are several treatments for the disease, current options for treating aggressive, therapy-resistant AML are limited and clini...
Nanozymes for different types of cancer. Key considerations in designing nanozymes for tumors include: specificity to the tumor; adjuvant therapy; mimetic activities and regulatory cell death (RCD) Full size image This review aims to provide a foundation for the future development of nanozymes by ide...
et al. Two transforming C-RAF germ-line mutations identified in patients with therapy-related acute myeloid leukemia. Cancer Res. 66, 3401–3408 (2006). Article CAS PubMed Google Scholar Diamond, E. L. et al. Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature 567, ...
One program Hopkins said excites Exscientia is EXS74539, a preclinical-stage selective and reversible lysine specific demethylase 1 (LSD1) inhibitor that the company is developing as a treatment for acute myeloid leukemia (AML) as well as small-cell lung cancer (SCLC). E...
genetic changes in the cancer cells of people with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The trial, funded by NIH's National Cancer Institute (NCI), aims to accelerate the discovery of more tailored treatments for these aggressive cancers of t...